Nocardia: Difference between revisions
From IDWiki
Nocardia
m (Text replacement - " species}}" to "") |
No edit summary |
||
(5 intermediate revisions by the same user not shown) | |||
Line 1: | Line 1: | ||
⚫ | |||
⚫ | |||
==Background== |
==Background== |
||
===Microbiology=== |
===Microbiology=== |
||
*Beaded [[Stain::Gram-positive]] [[Stain::partially acid-fast]] [[Shape::bacillus]] |
*Beaded [[Stain::Gram-positive]] [[Stain::partially acid-fast]] [[Shape::bacillus]] within the class [[Class::Actinobacteria]] and order [[Order::Corynebacteriales]] |
||
*Catalase [[Catalase::positive]] and lyzozyme resistant |
|||
⚫ | |||
*Has a classic beaded branching cell morphology |
|||
⚫ | |||
*Colonies are slow to grow and have a chalky white appearance |
|||
*Ubiquitous environmental saprophyte found in soil and water |
|||
=== Pathophysiology === |
|||
* Spores or mycelia are either inhaled into the lungs or directly inoculated in the skin and soft tissue |
|||
* Traumatic inoculation includes during motor vehicle collisions, mild scratches or pricks, or nosocomial with dirt entering through an open wound or central line |
|||
* Forms difficult-to-treat biofilms when involved in [[CLABSI|CLABSIs]] |
|||
=== Risk Factors === |
|||
* More common in immunocompromised (cell-mediated immunodeficiency including [[HIV]], hematologic malignancy, and transplant patients), though can also occur in immunocompetent who have [[COPD]], [[bronchiectasis]], and [[cystic fibrosis]] |
|||
* Among transplant recipients, [[lung transplant]] appears to be highest risk |
|||
* High-dose steroids and high levels of [[calcineurin inhibitors]] appear to be specific risk factors |
|||
* Also diabetes and alcohol use |
|||
== Clinical Manifestations == |
|||
=== Primary Cutaneous === |
|||
* Typically acquired by direct inoculation with soil |
|||
* [[Nocardia brasiliensis]] is the most common cause in North America |
|||
* May present with superficial soft tissue infection, including ulcer, abscess, cellulitis, pustules, plaques, or papules, most commonly on the arms and legs |
|||
* Can progress to lymphocutaneous infection with [[sporotrichoid lesions]] |
|||
=== Pulmonary === |
|||
* Subacute or chronic cough, dyspnea, fever, with or without pleuritic chest pain |
|||
* Most common form of disease in US |
|||
* Colonization also possible, particularly with patients who have structural lung changes like [[cystic fibrosis]] |
|||
* Starts with inflammation followed by formation of granulomas and necrotic abscesses |
|||
* Imaging typically showed lung nodules, lobar consolidation, and pleural effusion, and may show infiltrates and necrotizing granulomas |
|||
** Usually bilateral |
|||
** Cavitations more common in immunocompromised patients |
|||
=== Disseminated === |
|||
* Usually starts with a focal infection (skin or lung), which then disseminates hematogenously |
|||
* Most commonly involves skin, lungs, and CNS, but can also disseminate to kidney, joint, retina, and heart |
|||
* Much more common in immunosuppressed patients |
|||
=== CNS Disease === |
|||
* Most common site of hematogenous dissemination |
|||
* Presents with typical symptoms of fever, headache, meningismus, seizure, and focal neurologic deficits |
|||
* Can also be asymptomatic, so immunocompromised patients should get imaging and possibly LP |
|||
=== Other === |
|||
* [[Mycetoma]] |
|||
* [[Bacteremia]] |
|||
* Ocular infection, either from direct inoculation or hematogenous spread |
|||
* Bone and joint infection, primarily from dissemination |
|||
==Management== |
==Management== |
||
=== Further Evaluation === |
|||
* Consider screening MRI brain in all patients with disseminated or pulmonary disease regardless of neurologic symptoms |
|||
* Consider CT chest in all patients |
|||
* Consider assessment for immunodeficiency; at the very least, HIV testing and a good history |
|||
=== Antimicrobial Selection === |
|||
*Mild to moderate: [[Is treated by::TMP-SMX]] |
*Mild to moderate: [[Is treated by::TMP-SMX]] |
||
**Immunocompetent: 5-10 mg/kg split tid to qid |
**Immunocompetent: 5-10 mg/kg split tid to qid |
||
Line 23: | Line 82: | ||
* Serious pulmonary infection: 6 to 12 months or longer |
* Serious pulmonary infection: 6 to 12 months or longer |
||
* Any non-cutaneous disease in immunocompromised host: at least 12 months, and possibly lifelong suppression |
* Any non-cutaneous disease in immunocompromised host: at least 12 months, and possibly lifelong suppression |
||
=== Monitoring === |
|||
* Serial CT scans to assess response to therapy |
|||
⚫ | |||
⚫ |
Latest revision as of 22:05, 12 March 2023
Background
Microbiology
- Beaded Gram-positive partially acid-fast bacillus within the class Actinobacteria and order Corynebacteriales
- Catalase positive and lyzozyme resistant
- Has a classic beaded branching cell morphology
- Microscopic appearance similar to Actinomyces, differentiated by acid fast staining (Actinomyces is not acid fast)
- Colonies are slow to grow and have a chalky white appearance
- Ubiquitous environmental saprophyte found in soil and water
Pathophysiology
- Spores or mycelia are either inhaled into the lungs or directly inoculated in the skin and soft tissue
- Traumatic inoculation includes during motor vehicle collisions, mild scratches or pricks, or nosocomial with dirt entering through an open wound or central line
- Forms difficult-to-treat biofilms when involved in CLABSIs
Risk Factors
- More common in immunocompromised (cell-mediated immunodeficiency including HIV, hematologic malignancy, and transplant patients), though can also occur in immunocompetent who have COPD, bronchiectasis, and cystic fibrosis
- Among transplant recipients, lung transplant appears to be highest risk
- High-dose steroids and high levels of calcineurin inhibitors appear to be specific risk factors
- Also diabetes and alcohol use
Clinical Manifestations
Primary Cutaneous
- Typically acquired by direct inoculation with soil
- Nocardia brasiliensis is the most common cause in North America
- May present with superficial soft tissue infection, including ulcer, abscess, cellulitis, pustules, plaques, or papules, most commonly on the arms and legs
- Can progress to lymphocutaneous infection with sporotrichoid lesions
Pulmonary
- Subacute or chronic cough, dyspnea, fever, with or without pleuritic chest pain
- Most common form of disease in US
- Colonization also possible, particularly with patients who have structural lung changes like cystic fibrosis
- Starts with inflammation followed by formation of granulomas and necrotic abscesses
- Imaging typically showed lung nodules, lobar consolidation, and pleural effusion, and may show infiltrates and necrotizing granulomas
- Usually bilateral
- Cavitations more common in immunocompromised patients
Disseminated
- Usually starts with a focal infection (skin or lung), which then disseminates hematogenously
- Most commonly involves skin, lungs, and CNS, but can also disseminate to kidney, joint, retina, and heart
- Much more common in immunosuppressed patients
CNS Disease
- Most common site of hematogenous dissemination
- Presents with typical symptoms of fever, headache, meningismus, seizure, and focal neurologic deficits
- Can also be asymptomatic, so immunocompromised patients should get imaging and possibly LP
Other
- Mycetoma
- Bacteremia
- Ocular infection, either from direct inoculation or hematogenous spread
- Bone and joint infection, primarily from dissemination
Management
Further Evaluation
- Consider screening MRI brain in all patients with disseminated or pulmonary disease regardless of neurologic symptoms
- Consider CT chest in all patients
- Consider assessment for immunodeficiency; at the very least, HIV testing and a good history
Antimicrobial Selection
- Mild to moderate: TMP-SMX
- Immunocompetent: 5-10 mg/kg split tid to qid
- Immunocompromised: 15 mg/kg split tid to qid
- Severe: TMP-SMX plus either amikacin or imipenem
- Other antimicrobials include ceftriaxone, minocycline, and linezolid
Duration
- Isolated cutaneous infection in immunocompetent host: 3 to 6 months
- Isolated cutaneous infection in immunocompromised host: 6 to 12 months
- Serious pulmonary infection: 6 to 12 months or longer
- Any non-cutaneous disease in immunocompromised host: at least 12 months, and possibly lifelong suppression
Monitoring
- Serial CT scans to assess response to therapy
- Monitoring for antibiotic toxicity